HSV529 Vaccine in HSV-2 Seropositive Adults

Part of paid clinical trials in Seattle, Washington.

Sponsor
Fred Hutchinson Cancer Center
Study ID
NCT02571166
Phase
PHASE1
Status
Completed

Conditions

  • Herpes Simplex Virus 2

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Not accepted

Interventions

  • HSV529 — BIOLOGICAL
    Live, Replication-defective HSV-2 virus
  • Valacyclovir — DRUG
    500 mg orally, once daily for 4 weeks

Study Details

The purpose of the study is to determine the safety of HSV529 vaccine in healthy volunteers with HSV infection and to determine if administration of the HSV529 vaccine increases the immune response in genital skin.

Key Dates

Start date
Nov 30, 2015
Status verified
Jan 2019
Primary completion
Dec 1, 2018
Completion
Dec 1, 2018

Study Design

Enrollment
10 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: HSV529

Primary Outcome Measure

Safety of HSV529 vaccine assessed by solicited Adverse Events, non-solicited Adverse Events and all Serious Adverse Events. [ Time Frame: one year ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Washington Virology Research ClinicSeattleWashington98104-

Find similar trials in Seattle, WA

By research site
University of Washington Virology Research Clinic· Seattle, WA